Patterns of Care in Medical Oncology

What is your impression of the ECOG-E2100 study evaluating bevacizumab with paclitaxel as first-line therapy for metastatic disease?

Have you used bevacizumab for breast cancer patients in the metastatic setting?

Have you used bevacizumab for breast cancer patients in the metastatic setting?

Which of the following best explains the reasons you have not yet used bevacizumab?*

Which of the following best explains the reasons you have not yet used bevacizumab?*

In how many patients with the following tumor types have you used bevacizumab?

For the breast cancer patients with whom you used bevacizumab: How many received it?*

If you have used or plan to use bevacizumab in metastatic breast cancer, which agents would you combine with it?*

If you have used or plan to use bevacizumab, for how long would you use it?*

The cost of bevacizumab is so high that it should not be prescribed in the metastatic breast cancer setting even if reimbursement were not an issue.

If reimbursement and cost were not an issue, would you recommend bevacizumab for a 65-year-old woman who received prior AC and presents with asymptomatic metastatic breast cancer with: (Percent answering yes)

For a patient who has received adjuvant AC and has disease recurrence, in whom you want to utilize a single-agent taxane, which of the following best describes which agent and schedule you would most likely use?

Do you use capecitabine for metastatic breast cancer in your practice?

How do you generally schedule capecitabine in this setting?*

How do you generally dose capecitabine monotherapy when using it in a 2 weeks on/1 week off schedule?*

Have you used capecitabine plus bevacizumab off protocol in the metastatic setting?*

If yes, with how many patients in the last year?*

For a patient who presents with asymptomatic metastatic disease and no prior systemic therapy, how would you generally compare the following?* Capecitabine (C) versus capecitabine plus bevacizumab (B)

For a patient who presents with asymptomatic metastatic disease and no prior systemic therapy, how would you generally compare the following?* Capecitabine (C) versus capecitabine plus bevacizumab (B)

For a patient who presents with asymptomatic metastatic disease and no prior systemic therapy, how would you generally compare the following?* Capecitabine (C) versus paclitaxel (P)

For a patient who presents with asymptomatic metastatic disease and no prior systemic therapy, how would you generally compare the following?* Capecitabine (C) versus paclitaxel (P)

For a patient who presents with asymptomatic metastatic disease and no prior systemic therapy, how would you generally compare the following?* Capecitabine (C) versus docetaxel (D)

For a patient who presents with asymptomatic metastatic disease and no prior systemic therapy, how would you generally compare the following?* Capecitabine (C) versus docetaxel (D)

For a patient who presents with asymptomatic metastatic disease and no prior systemic therapy, how would you generally compare the following?* Capecitabine (C) versus capecitabine plus docetaxel (D)

For a patient who presents with asymptomatic metastatic disease and no prior systemic therapy, how would you generally compare the following?* Capecitabine (C) versus capecitabine plus docetaxel (D)

For a patient who presents with asymptomatic metastatic disease and no prior systemic therapy, how would you generally compare the following?* Capecitabine (C) versus vinorelbine (V)

For a patient who presents with asymptomatic metastatic disease and no prior systemic therapy, how would you generally compare the following?* Capecitabine (C) versus vinorelbine (V)

For a patient who presents with asymptomatic metastatic disease and no prior systemic therapy, how would you generally compare the following?* Paclitaxel (P) versus paclitaxel plus bevacizumab (B)

For a patient who presents with asymptomatic metastatic disease and no prior systemic therapy, how would you generally compare the following?* Paclitaxel (P) versus paclitaxel plus bevacizumab (B)

Assume that you are presented with a breast cancer patient who is 55 years old with asymptomatic lung mets and has been started on capecitabine, 2,000 mg/m2 in two divided doses of 2 weeks on then 1 week off. After 3 cycles, she has had no changes in the lesions and no side effects. Which of the following best describes what you would generally do?*

Same as above but after 3 cycles, she is having an objective response in the lungs but complains of mild pain and redness in her hands and feet. Which of the following best describes what you would generally do?*

About what percentage of breast cancer patients treated with capecitabine in your experience have side effects requiring dose reduction?*

Which first-line endocrine therapy, if any, would you generally use in postmenopausal patients with metastases?

Which first-line endocrine therapy, if any, would you generally use in postmenopausal patients with metastases?

Which first-line endocrine therapy, if any, would you generally use in postmenopausal patients with metastases?

Which first-line endocrine therapy, if any, would you generally use in postmenopausal patients with metastases?

Which first-line endocrine therapy, if any, would you generally use in progression after 4 years of adjuvant anastrozole?

When utilizing fulvestrant in the metastatic setting, do you generally use a loading dose?*

If you do not generally use a loading dose, is cost and reimbursement the primary reason?*

Which of the following best describes how you dose fulvestrant?*

Have you had problems with reimbursement for the loading dose of fulvestrant?*